ATE446962T1 - Thiazolopyridinon-derivate als mch- rezeptorantagonisten - Google Patents

Thiazolopyridinon-derivate als mch- rezeptorantagonisten

Info

Publication number
ATE446962T1
ATE446962T1 AT05854554T AT05854554T ATE446962T1 AT E446962 T1 ATE446962 T1 AT E446962T1 AT 05854554 T AT05854554 T AT 05854554T AT 05854554 T AT05854554 T AT 05854554T AT E446962 T1 ATE446962 T1 AT E446962T1
Authority
AT
Austria
Prior art keywords
thiazolopyridinone
derivatives
receptor antagonists
mch receptor
amelioration
Prior art date
Application number
AT05854554T
Other languages
English (en)
Inventor
Albert Amegadzie
James Beck
Kevin Gardinier
Erik Hembre
James Ruble
Kenneth Savin
Brian Wakefield
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE446962T1 publication Critical patent/ATE446962T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05854554T 2004-12-17 2005-12-16 Thiazolopyridinon-derivate als mch- rezeptorantagonisten ATE446962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63714304P 2004-12-17 2004-12-17
PCT/US2005/045866 WO2006066174A1 (en) 2004-12-17 2005-12-16 Thiazolopyridinone derivates as mch receptor antagonists

Publications (1)

Publication Number Publication Date
ATE446962T1 true ATE446962T1 (de) 2009-11-15

Family

ID=36123161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854554T ATE446962T1 (de) 2004-12-17 2005-12-16 Thiazolopyridinon-derivate als mch- rezeptorantagonisten

Country Status (12)

Country Link
US (1) US7902356B2 (de)
EP (1) EP1828207B1 (de)
JP (1) JP5072602B2 (de)
CN (1) CN101080411B (de)
AT (1) ATE446962T1 (de)
AU (1) AU2005316314B2 (de)
BR (1) BRPI0519124A2 (de)
CA (1) CA2589695A1 (de)
DE (1) DE602005017423D1 (de)
ES (1) ES2333243T3 (de)
MX (1) MX2007007227A (de)
WO (1) WO2006066174A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582327A1 (en) 2004-10-01 2006-04-13 Takao Suzuki 2-arylcarboxamide-nitrogeneous heterocycle compound
EP1983980A4 (de) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp Thiazol- und thiadiazol-verbindungen für verwendungen in verbindung mit entzündung und immunität
JP5198439B2 (ja) * 2006-06-08 2013-05-15 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
KR20090082484A (ko) * 2006-12-14 2009-07-30 일라이 릴리 앤드 캄파니 5-[4-(아제티딘-3-일옥시)-페닐]-2-페닐-5ｈ-티아졸로[5,4-ｃ]피리딘-4-온 유도체 및 ｍｃｈ 수용체 길항제로서의 이들의 용도
JP5514716B2 (ja) * 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
DE102007028925A1 (de) * 2007-06-22 2008-12-24 Saltigo Gmbh Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
JPWO2010024258A1 (ja) 2008-08-29 2012-01-26 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体
CN102666551B (zh) 2009-12-18 2014-12-10 詹森药业有限公司 作为mglur5受体的变构调节剂的双环噻唑
CA2782950A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
SG10201505540SA (en) 2010-07-16 2015-08-28 Abbott Lab Process for preparing antiviral compounds
UA113498C2 (xx) 2010-07-16 2017-02-10 Фосфінові ліганди для каталітичних реакцій
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
CN102532123B (zh) * 2010-12-29 2016-03-09 中国医学科学院药物研究所 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途
WO2012109573A1 (en) * 2011-02-11 2012-08-16 Purdue Research Foundation Substituted thiazoles for use as antiviral agents
US9307767B2 (en) * 2012-03-27 2016-04-12 Bayer Intellectual Property Gmbh Herbicidally and insecticidally active thiazolopyridinones
JPWO2013168759A1 (ja) * 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
PL3805233T3 (pl) 2014-01-13 2024-06-10 Aurigene Oncology Limited ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
WO2015138276A2 (en) * 2014-03-10 2015-09-17 Innov17 Llc Retinoic acid receptor-related orphan receptor modulators and uses thereof
US20150252051A1 (en) * 2014-03-10 2015-09-10 Innov17 Llc Retinoic acid receptor-related orphan receptor modulators and uses thereof
CU20180006A7 (es) * 2015-07-15 2018-06-05 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de irak-4
RU2766139C2 (ru) * 2016-03-11 2022-02-08 Ац Иммуне Са Бициклические соединения для диагностики и лечения
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
JP7241747B2 (ja) 2017-10-31 2023-03-17 キュリス，インコーポレイテッド 血液学的障害を治療するための化合物および組成物
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
IL307258A (en) 2021-04-05 2023-11-01 Halia Therapeutics Inc NEK7 inhibitors
CN117120054A (zh) 2021-04-08 2023-11-24 柯里斯公司 治疗癌症的组合疗法
US20250177382A1 (en) 2021-04-22 2025-06-05 Halia Therapeutics, Inc. Nek7 inhibitors
CN115403456B (zh) * 2022-09-22 2023-11-17 成都大学 一种合成爱德万甜中间体3-羟基-4-甲氧基苯丙醛的方法
CN119592965B (zh) * 2024-12-10 2025-09-26 西安交通大学 一种基于电合成的羟基酮类化合物的制备方法及其制备的羟基酮类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0867678A (ja) * 1993-11-10 1996-03-12 Takeda Chem Ind Ltd 複素環アミド化合物、その製造法および剤
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
CA2509042A1 (en) 2002-12-11 2004-06-24 Eli Lilly And Company Novel mch receptor antagonists
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
BRPI0517425A (pt) * 2004-12-17 2008-10-07 Lilly Co Eli composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
EP1987020B1 (de) 2006-02-15 2012-10-03 Sanofi Azacyclylsubstituierte aryldihydroisochinolinone, verfahren zu ihrer herstellung und ihre verwendung als medikamente

Also Published As

Publication number Publication date
BRPI0519124A2 (pt) 2008-12-23
AU2005316314B2 (en) 2011-06-23
EP1828207B1 (de) 2009-10-28
CN101080411A (zh) 2007-11-28
JP5072602B2 (ja) 2012-11-14
MX2007007227A (es) 2007-08-21
ES2333243T3 (es) 2010-02-18
JP2008524250A (ja) 2008-07-10
CA2589695A1 (en) 2006-06-22
WO2006066174A1 (en) 2006-06-22
US7902356B2 (en) 2011-03-08
CN101080411B (zh) 2011-11-02
DE602005017423D1 (de) 2009-12-10
AU2005316314A1 (en) 2006-06-22
US20090233919A1 (en) 2009-09-17
EP1828207A1 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
DK1828177T3 (da) Hidtil ukendte MCH-receptorantagonister
WO2007146758A3 (en) Novel mch receptor antagonists
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
ATE399770T1 (de) Tachykininrezeptorantagonisten
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
DE602008001983D1 (de) Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
DE602005023197D1 (de) -muscarinrezeptors
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
WO2005040157A3 (en) Novel mch receptor antagonists
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
ATE399164T1 (de) Antagonisten des opioidrezeptors
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
EA200970189A1 (ru) Пирролидинонанилины как модуляторы прогестероновых рецепторов
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
EA015500B9 (ru) Новые антагонисты мсн рецепторов
ATE486078T1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties